Table 3 Disproportionality analysis for acute kidney injury associated with vancomycin and diuretics.

From: Drug–drug interaction signals between loop diuretics and teicoplanin during acute kidney injury evaluated using Japanese spontaneous adverse drug event reports

 

AKI

Without AKI

Crude ROR

95% CI

Adjusted ROR

95% CI

p-value

Loop diuretics

 VCM

432

3312

4.14

3.75–4.59

3.97

3.57–4.40

 < 0.0001

 Loop diuretics

2350

29,354

2.54

2.43–2.66

1.90

1.81–2.00

 < 0.0001

 VCM + loop diuretics

83

657

4.01

3.19–5.05

3.61

2.86–4.55

 < 0.0001

 Non-target drugs

20,060

637,366

1.00

–

1.00

–

–

Thiazide diuretics

 VCM

514

3924

3.96

3.61–4.35

3.73

3.39–4.11

 < 0.0001

 Thiazide diuretics

597

7111

2.54

2.33–2.76

1.77

1.62–1.93

 < 0.0001

 VCM + thiazide diuretics

1

45

0.67

0.09–4.88

0.52

0.07–3.82

0.5241

 Non-target drugs

21,813

659,609

1.00

–

1.00

–

–

Thiazide-like diuretics

 VCM

514

3961

3.87

3.53–4.25

3.67

3.33–4.04

 < 0.0001

 Thiazide-like diuretics

110

1393

2.36

1.94–2.86

1.61

1.32–1.96

 < 0.0001

 VCM + thiazide-like diuretics

1

8

3.73

0.47–29.8

1.66

0.20–13.8

0.6370

 Non-target drugs

22,300

665,327

1.00

–

1.00

–

–

Potassium-sparing diuretics

 VCM

483

3742

3.97

3.61–4.37

3.77

3.41–4.16

 < 0.0001

 Potassium-sparing diuretics

1173

12,890

2.80

2.64–2.98

2.14

2.01–2.29

 < 0.0001

 VCM + potassium-sparing diuretics

32

227

4.34

3.00–6.29

3.96

2.72–5.76

 < 0.0001

 Non-target drugs

21,237

653,830

1.00

–

1.00

–

–

Vaptans

 VCM

510

3946

3.90

3.55–4.28

3.70

3.36–4.07

 < 0.0001

 Vaptans

427

3093

4.17

3.76–4.62

2.51

2.25–2.80

 < 0.0001

 VCM + vaptans

5

23

6.56

2.49–17.3

4.18

1.57–11.1

0.0042

 Non-target drugs

21,983

663,627

1.00

–

1.00

–

–

  1. The number of patients with and without AKI in each category was presented. The target drugs were VCM with intravenous administration and diuretics. A multivariate logistic regression model was used to determine the adjusted ROR by introducing age, sex, reporting year, and co-existing diseases (chronic kidney disease, hypertension, diabetes, cardiac failure, and sepsis).
  2. AKI acute kidney injury, ROR reporting odds ratio, 95% CI 95% confidence interval, VCM vancomycin.
Back to article page